@article{ElHelouBiegnerBodeetal.2019,
  author    = {El-Helou, Sabine M. and Biegner, Anika-Kerstin and Bode, Sebastian and Ehl, Stephan R. and Heeg, Maximilian and Maccari, Maria E. and Ritterbusch, Henrike and Speckmann, Carsten and Rusch, Stephan and Scheible, Raphael and Warnatz, Klaus and Atschekzei, Faranaz and Beider, Renata and Ernst, Diana and Gerschmann, Stev and Jablonka, Alexandra and Mielke, Gudrun and Schmidt, Reinhold E. and Sch{\"u}rmann, Gesine and Sogkas, Georgios and Baumann, Ulrich H. and Klemann, Christian and Viemann, Dorothee and Bernuth, Horst von and Kr{\"u}ger, Renate and Hanitsch, Leif G. and Scheibenbogen, Carmen M. and Wittke, Kirsten and Albert, Michael H. and Eichinger, Anna and Hauck, Fabian and Klein, Christoph and Rack-Hoch, Anita and Sollinger, Franz M. and Avila, Anne and Borte, Michael and Borte, Stephan and Fasshauer, Maria and Hauenherm, Anja and Kellner, Nils and M{\"u}ller, Anna H. and {\"U}lzen, Anett and Bader, Peter and Bakhtiar, Shahrzad and Lee, Jae-Yun and Heß, Ursula and Schubert, Ralf and W{\"o}lke, Sandra and Zielen, Stefan and Ghosh, Sujal and Laws, Hans-Juergen and Neubert, Jennifer and Oommen, Prasad T. and H{\"o}nig, Manfred and Schulz, Ansgar and Steinmann, Sandra and Klaus, Schwarz and D{\"u}ckers, Gregor and Lamers, Beate and Langemeyer, Vanessa and Niehues, Tim and Shai, Sonu and Graf, Dagmar and M{\"u}glich, Carmen and Schmalzing, Marc T. and Schwaneck, Eva C. and Tony, Hans-Peter and Dirks, Johannes and Haase, Gabriele and Liese, Johannes G. and Morbach, Henner and Foell, Dirk and Hellige, Antje and Wittkowski, Helmut and Masjosthusmann, Katja and Mohr, Michael and Geberzahn, Linda and Hedrich, Christian M. and M{\"u}ller, Christiane and R{\"o}sen-Wolff, Angela and Roesler, Joachim and Zimmermann, Antje and Behrends, Uta and Rieber, Nikolaus and Schauer, Uwe and Handgretinger, Rupert and Holzer, Ursula and Henes, J{\"o}rg and Kanz, Lothar and Boesecke, Christoph and Rockstroh, J{\"u}rgen K. and Schwarze-Zander, Carolynne and Wasmuth, Jan-Christian and Dilloo, Dagmar and H{\"u}lsmann, Brigitte and Sch{\"o}nberger, Stefan and Schreiber, Stefan and Zeuner, Rainald and Ankermann, Tobias and Bismarck, Philipp von and Huppertz, Hans-Iko and Kaiser-Labusch, Petra and Greil, Johann and Jakoby, Donate and Kulozik, Andreas E. and Metzler, Markus and Naumann-Bartsch, Nora and Sobik, Bettina and Graf, Norbert and Heine, Sabine and Kobbe, Robin and Lehmberg, Kai and M{\"u}ller, Ingo and Herrmann, Friedrich and Horneff, Gerd and Klein, Ariane and Peitz, Joachim and Schmidt, Nadine and Bielack, Stefan and Groß-Wieltsch, Ute and Classen, Carl F. and Klasen, Jessica and Deutz, Peter and Kamitz, Dirk and Lassy, Lisa and Tenbrock, Klaus and Wagner, Norbert and Bernbeck, Benedikt and Brummel, Bastian and Lara-Villacanas, Eusebia and M{\"u}nstermann, Esther and Schneider, Dominik T. and Tietsch, Nadine and Westkemper, Marco and Weiß, Michael and Kramm, Christof and K{\"u}hnle, Ingrid and Kullmann, Silke and Girschick, Hermann and Specker, Christof and Vinnemeier-Laubenthal, Elisabeth and Haenicke, Henriette and Schulz, Claudia and Schweigerer, Lothar and M{\"u}ller, Thomas G. and Stiefel, Martina and Belohradsky, Bernd H. and Soetedjo, Veronika and Kindle, Gerhard and Grimbacher, Bodo},
  title     = {The German national registry of primary immunodeficiencies (2012-2017)},
  series = {Frontiers in Immunology},
  volume    = {10},
  journal   = {Frontiers in Immunology},
  doi       = {10.3389/fimmu.2019.01272},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-226629},
  year      = {2019},
  abstract  = {Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs. Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel. Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1-25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57\% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36\% of patients. Familial cases were observed in 21\% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0-88 years). Presenting symptoms comprised infections (74\%) and immune dysregulation (22\%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE-syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49\% of all patients received immunoglobulin G (IgG) substitution (70\%-subcutaneous; 29\%-intravenous; 1\%-unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy. Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.},
  language  = {en}
}
@article{DimopoulosWeiselSongetal.2015,
  author    = {Dimopoulos, Meletios A. and Weisel, Katja C. and Song, Kevin W. and Delforge, Michel and Karlin, Lionel and Goldschmidt, Hartmut and Moreau, Philippe and Banos, Anne and Oriol, Albert and Garderet, Laurent and Cavo, Michele and Ivanova, Valentina and Alegre, Adrian and Martinez-Lopez, Joaquin and Chen, Christine and Spencer, Andrew and Knop, Stefan and Bahlis, Nizar J. and Renner, Christoph and Yu, Xin and Hong, Kevin and Sternas, Lars and Jacques, Christian and Zaki, Mohamed H. and San Miguel, Jesus F.},
  title     = {Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone},
  series = {Haematologica},
  volume    = {100},
  journal   = {Haematologica},
  number    = {10},
  doi       = {10.3324/haematol.2014.117077},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-140349},
  pages     = {1327 -- 1333},
  year      = {2015},
  abstract  = {Patients with refractory or relapsed and refractory multiple myeloma who no longer receive benefit from novel agents have limited treatment options and short expected survival. del(17p) and t(4;14) are correlated with shortened survival. The phase 3 MM-003 trial demonstrated significant progression-free and overall survival benefits from treatment with pomalidomide plus low-dose dexamethasone compared to high-dose dexamethasone among patients in whom bortezomib and lenalidomide treatment had failed. At an updated median follow-up of 15.4 months, the progression-free survival was 4.0 versus 1.9 months (HR, 0.50; P<0.001), and median overall survival was 13.1 versus 8.1 months (HR, 0.72; P=0.009). Pomalidomide plus low-dose dexamethasone, compared with high-dose dexamethasone, improved progression-free survival in patients with del(17p) (4.6 versus 1.1 months; HR, 0.34; P < 0.001), t(4;14) (2.8 versus 1.9 months; HR, 0.49; P=0.028), and in standard-risk patients (4.2 versus 2.3 months; HR, 0.55; P<0.001). Although the majority of patients treated with high-dose dexamethasone took pomalidomide after discontinuation, the overall survival of patients treated with pomalidomide plus low-dose dexamethasone or highdose dexamethasone was 12.6 versus 7.7 months (HR, 0.45; P=0.008) in patients with del(17p), 7.5 versus 4.9 months (HR, 1.12; P=0.761) in those with t(4;14), and 14.0 versus 9.0 months (HR, 0.85; P=0.380) in standard-risk subjects. The overall response rate was higher in patients treated with pomalidomide plus low-dose dexamethasone than in those treated with high-dose dexamethasone both among standard-risk patients (35.2\% versus 9.7\%) and those with del(17p) (31.8\% versus 4.3\%), whereas it was similar in patients with t(4; 14) (15.9\% versus 13.3\%). The safety of pomalidomide plus low-dose dexamethasone was consistent with initial reports. In conclusion, pomalidomide plus low-dose dexamethasone is efficacious in patients with relapsed/refractory multiple myeloma and del(17p) and/or t(4;14).},
  language  = {en}
}
@article{HoppAlbertWeissenbergerMencletal.2016,
  author    = {Hopp, Sarah and Albert-Weissenberger, Christiane and Mencl, Stine and Bieber, Michael and Schuhmann, Michael K. and Stetter, Christian and Nieswandt, Bernhard and Schmidt, Peter M. and Monoranu, Camelia-Maria and Alafuzoff, Irina and Marklund, Niklas and Nolte, Marc W. and Sir{\´e}n, Anna-Leena and Kleinschnitz, Christoph},
  title     = {Targeting coagulation factor XII as a novel therapeutic option in brain trauma},
  series = {Annals of Neurology},
  volume    = {79},
  journal   = {Annals of Neurology},
  number    = {6},
  doi       = {10.1002/ana.24655},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-188800},
  pages     = {970-982},
  year      = {2016},
  abstract  = {Objective: Traumatic brain injury is a major global public health problem for which specific therapeutic interventions are lacking. There is, therefore, a pressing need to identify innovative pathomechanism-based effective therapies for this condition. Thrombus formation in the cerebral microcirculation has been proposed to contribute to secondary brain damage by causing pericontusional ischemia, but previous studies have failed to harness this finding for therapeutic use. The aim of this study was to obtain preclinical evidence supporting the hypothesis that targeting factor XII prevents thrombus formation and has a beneficial effect on outcome after traumatic brain injury. Methods: We investigated the impact of genetic deficiency of factor XII and acute inhibition of activated factor XII with a single bolus injection of recombinant human albumin-fused infestin-4 (rHA-Infestin-4) on trauma-induced microvascular thrombus formation and the subsequent outcome in 2 mouse models of traumatic brain injury. Results: Our study showed that both genetic deficiency of factor XII and an inhibition of activated factor XII in mice minimize trauma-induced microvascular thrombus formation and improve outcome, as reflected by better motor function, reduced brain lesion volume, and diminished neurodegeneration. Administration of human factor XII in factor XII-deficient mice fully restored injury-induced microvascular thrombus formation and brain damage. Interpretation: The robust protective effect of rHA-Infestin-4 points to a novel treatment option that can decrease ischemic injury after traumatic brain injury without increasing bleeding tendencies.},
  language  = {en}
}
@article{IsraelOhsiekAlMomanietal.2016,
  author    = {Israel, Ina and Ohsiek, Andrea and Al-Momani, Ehab and Albert-Weissenberger, Christiane and Stetter, Christian and Mencl, Stine and Buck, Andreas K. and Kleinschnitz, Christoph and Samnick, Samuel and Sir{\´e}n, Anna-Leena},
  title     = {Combined [\(^{18}\)F]DPA-714 micro-positron emission tomography and autoradiography imaging of microglia activation after closed head injury in mice},
  series = {Journal of Neuroinflammation},
  volume    = {13},
  journal   = {Journal of Neuroinflammation},
  number    = {140},
  doi       = {10.1186/s12974-016-0604-9},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-146606},
  year      = {2016},
  abstract  = {Background Traumatic brain injury (TBI) is a major cause of death and disability. Neuroinflammation contributes to acute damage after TBI and modulates long-term evolution of degenerative and regenerative responses to injury. The aim of the present study was to evaluate the relationship of microglia activation to trauma severity, brain energy metabolism, and cellular reactions to injury in a mouse closed head injury model using combined in vivo PET imaging, ex vivo autoradiography, and immunohistochemistry. Methods A weight-drop closed head injury model was used to produce a mixed diffuse and focal TBI or a purely diffuse mild TBI (mTBI) in C57BL6 mice. Lesion severity was determined by evaluating histological damage and functional outcome using a standardized neuroscore (NSS), gliosis, and axonal injury by immunohistochemistry. Repeated intra-individual in vivo μPET imaging with the specific 18-kDa translocator protein (TSPO) radioligand [\(^{18}\)F]DPA-714 was performed on day 1, 7, and 16 and [\(^{18}\)F]FDG-μPET imaging for energy metabolism on days 2-5 after trauma using freshly synthesized radiotracers. Immediately after [\(^{18}\)F]DPA-714-μPET imaging on days 7 and 16, cellular identity of the [\(^{18}\)F]DPA-714 uptake was confirmed by exposing freshly cut cryosections to film autoradiography and successive immunostaining with antibodies against the microglia/macrophage marker IBA-1. Results Functional outcome correlated with focal brain lesions, gliosis, and axonal injury. [\(^{18}\)F]DPA-714-μPET showed increased radiotracer uptake in focal brain lesions on days 7 and 16 after TBI and correlated with reduced cerebral [\(^{18}\)F]FDG uptake on days 2-5, with functional outcome and number of IBA-1 positive cells on day 7. In autoradiography, [\(^{18}\)F]DPA-714 uptake co-localized with areas of IBA1-positive staining and correlated strongly with both NSS and the number of IBA1-positive cells, gliosis, and axonal injury. After mTBI, numbers of IBA-1 positive cells with microglial morphology increased in both brain hemispheres; however, uptake of [\(^{18}\)F]DPA-714 was not increased in autoradiography or in μPET imaging. Conclusions [\(^{18}\)F]DPA-714 uptake in μPET/autoradiography correlates with trauma severity, brain metabolic deficits, and microglia activation after closed head TBI.},
  language  = {en}
}
@phdthesis{Albert2012,
  author    = {Albert, Christian Robert},
  title     = {N,C-verkn{\"u}pfte Arylisochinoline: Synthese und Optimierung der biologischen Aktivit{\"a}ten sowie Strukturaufkl{\"a}rung von Naturstoffen durch HPLC-NMR- und HPLC-MS/MS-Kopplung},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-76537},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2012},
  abstract  = {Tropische Infektionskrankheiten wie Malaria, Leishmaniose oder auch die Afrikanische Trypanosomiase sind aufgrund von zunehmenden Resistenzen der Erreger, globaler Erw{\"a}rmung, aber auch von Vers{\"a}umnissen in der Vergangenheit bei der kontinuierlichen Weiterentwicklung bestehender sowie der Erforschung neuer Medikamente auch im 21. Jahrhundert noch eine große Bedrohung f{\"u}r Millionen von Menschen. Die Suche nach neuartigen Wirkstoffen und deren Weiterentwicklung zu potenziellen Medikamenten ist daher zwingend erforderlich. Insbesondere Produkte des Sekund{\"a}rstoffwechsels wie etwa die Alkaloide bilden wichtige Grundlagen als Leitstrukturen f{\"u}r pharmazeutische Wirkstoffe. Eine solche Klasse phytochemischen Ursprungs sind die Naphthylisochinolin-Alkaloide mit interessanten strukturellen Eigenschaften sowie pharmakologischen Wirksamkeiten. Einige Vertreter zeigen ausgepr{\"a}gte In-vitro-Aktivit{\"a}ten gegen protozoische Erreger wie Plasmodien, Leishmanien und Trypanosomen. Besonders die neuartige Unterklasse ionischer N,C-verkn{\"u}pfter Naphthylisochinolin-Alkaloide, wie z.B. Ancistrocladinium A und Ancistrocladinium B, zeichnen sich durch gute antileishmaniale Wirkungen aus. In Vorarbeiten zeigten erste Studien zu Struktur-Aktivit{\"a}ts-Beziehungen (SAR-Studien) mit vereinfachten N,C-gekuppelten Arylisochinolinen, dass sich durch gezielte Strukturvariation die Aktivit{\"a}t gegen einen Erreger verbessern l{\"a}sst. Zus{\"a}tzlich wurde mit ersten Untersuchungen zum Wirkmechanismus dieser interessanten Verbindungen begonnen. Dar{\"u}ber hinaus erm{\"o}glicht die kontinuierliche Verbesserung der analytischen Methoden inzwischen die schnelle und gezielte Suche nach neuen Verbindungen aus der Natur. Durch die Anwendung von Online-Analyse-Verfahren, wie z.B. die Kopplung von HPLC mit NMR und MS, gelingt die Aufkl{\"a}rung der Konstitution von Substanzen direkt aus Extrakten. Ziel der vorliegenden Arbeit war die Verbesserung der biologischen Aktivit{\"a}ten der N,C-verkn{\"u}pften Arylisochinoline durch strukturelle Derivatisierung sowie Beitr{\"a}ge zur Aufkl{\"a}rung des Wirkmechanismus mittels markierter Verbindungen. Zus{\"a}tzlich sollten Naturstoffe unter Verwendung moderner HPLC-Kopplungstechniken untersucht und strukturell aufgekl{\"a}rt werden.},
  subject      = {HPLC},
  language  = {de}
}
@article{AlbertWeissenbergerStetterMeuthetal.2012,
  author    = {Albert-Weissenberger, Christiane and Stetter, Christian and Meuth, Sven G. and G{\"o}bel, Kerstin and Bader, Michael and Sir{\´e}n, Anna-Leena and Kleinschnitz, Christoph},
  title     = {Blocking of Bradykinin Receptor B1 Protects from Focal Closed Head Injury in Mice by Reducing Axonal Damage and Astroglia Activation},
  series = {Journal of Cerebral Blood Flow and Metabolism},
  volume    = {32},
  journal   = {Journal of Cerebral Blood Flow and Metabolism},
  number    = {9},
  doi       = {10.1038/jcbfm.2012.62},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-125903},
  pages     = {1747-1756},
  year      = {2012},
  abstract  = {The two bradykinin receptors B1R and B2R are central components of the kallikrein-kinin system with different expression kinetics and binding characteristics. Activation of these receptors by kinins triggers inflammatory responses in the target organ and in most situations enhances tissue damage. We could recently show that blocking of B1R, but not B2R, protects from cortical cryolesion by reducing inflammation and edema formation. In the present study, we investigated the role of B1R and B2R in a closed head model of focal traumatic brain injury (TBI; weight drop). Increased expression of B1R in the injured hemispheres of wild-type mice was restricted to the later stages after brain trauma, i.e. day 7 (P<0.05), whereas no significant induction could be observed for the B2R (P>0.05). Mice lacking the B1R, but not the B2R, showed less functional deficits on day 3 (P<0.001) and day 7 (P<0.001) compared with controls. Pharmacological blocking of B1R in wild-type mice had similar effects. Reduced axonal injury and astroglia activation could be identified as underlying mechanisms, while inhibition of B1R had only little influence on the local inflammatory response in this model. Inhibition of B1R may become a novel strategy to counteract trauma-induced neurodegeneration.},
  language  = {en}
}
@article{vanKoolwijkRamdasIkrametal.2012,
  author    = {van Koolwijk, Leonieke M. E. and Ramdas, Wishal D. and Ikram, M. Kamran and Jansonius, Nomdo M. and Pasutto, Francesca and Hys, Pirro G. and Macgregor, Stuart and Janssen, Sarah F. and Hewitt, Alex W. and Viswanathan, Ananth C. and ten Brink, Jacoline B. and Hosseini, S. Mohsen and Amin, Najaf and Despriet, Dominiek D. G. and Willemse-Assink, Jacqueline J. M. and Kramer, Rogier and Rivadeneira, Fernando and Struchalin, Maksim and Aulchenko, Yurii S. and Weisschuh, Nicole and Zenkel, Matthias and Mardin, Christian Y. and Gramer, Eugen and Welge-L{\"u}ssen, Ulrich and Montgomery, Grant W. and Carbonaro, Francis and Young, Terri L. and Bellenguez, C{\´e}line and McGuffin, Peter and Foster, Paul J. and Topouzis, Fotis and Mitchell, Paul and Wang, Jie Jin and Wong, Tien Y. and Czudowska, Monika A. and Hofman, Albert and Uitterlinden, Andre G. and Wolfs, Roger C. W. and de Jong, Paulus T. V. M. and Oostra, Ben A. and Paterson, Andrew D. and Mackey, David A. and Bergen, Arthur A. B. and Reis, Andre and Hammond, Christopher J. and Vingerling, Johannes R. and Lemij, Hans G. and Klaver, Caroline C. W. and van Duijn, Cornelia M.},
  title     = {Common Genetic Determinants of Intraocular Pressure and Primary Open-Angle Glaucoma},
  series = {PLoS Genetics},
  volume    = {8},
  journal   = {PLoS Genetics},
  number    = {5},
  doi       = {10.1371/journal.pgen.1002611},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-131378},
  pages     = {e1002611},
  year      = {2012},
  abstract  = {Intraocular pressure (IOP) is a highly heritable risk factor for primary open-angle glaucoma and is the only target for current glaucoma therapy. The genetic factors which determine IOP are largely unknown. We performed a genome-wide association study for IOP in 11,972 participants from 4 independent population-based studies in The Netherlands. We replicated our findings in 7,482 participants from 4 additional cohorts from the UK, Australia, Canada, and the Wellcome Trust Case-Control Consortium 2/Blue Mountains Eye Study. IOP was significantly associated with rs11656696, located in GAS7 at 17p13.1 (p = 1.4 x 10\(^{-8}\)), and with rs7555523, located in TMCO1 at 1q24.1 (p = 1.6 x 10\(^{-8}\)). In a meta-analysis of 4 case-control studies (total N = 1,432 glaucoma cases), both variants also showed evidence for association with glaucoma (p = 2.4 x 10\(^{-2}\) for rs11656696 and p = 9.1 x 10\(^{-4}\) for rs7555523). GAS7 and TMCO1 are highly expressed in the ciliary body and trabecular meshwork as well as in the lamina cribrosa, optic nerve, and retina. Both genes functionally interact with known glaucoma disease genes. These data suggest that we have identified two clinically relevant genes involved in IOP regulation.},
  language  = {en}
}
@article{AlbertBerningBurschkaetal.1984,
  author    = {Albert, Bernhard and Berning, Wilfried and Burschka, Christian and H{\"u}nig, Siegfried and Prokschy, Frank},
  title     = {Azobr{\"u}cken aus Azinen, IV. Intramolekulare [2 + 2]-Photocycloaddition zwischen parallelen C = C- und N = N-Bindungen},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-31314},
  year      = {1984},
  abstract  = {In den starren Molek{\"u}len 1- 10 reagieren die benachbarten parallelen C = C- und N = N-Bindungen nahezu quantitativ unter Photocyclisierung lU den l,2-Diazetidinen 11-10, deren Struktur spektroskopisch und f{\"u}r 13 durch Kristallstrukturanalyse bewiesen wird. Die in Abwesenheit der C = C-Bindung beobachtete Photo-Denitrogenierung unterbleibt selbst bei den empfindlichen Derivaten des 2,3-Diazabicyclo[2.2.11heptens. Photocyclisierung von 6 mit lwei zur N=N· Bindung benachbarten C=C-Bindungen tritt nur mit der Norbornendoppelbindung ein.},
  subject      = {Chemie},
  language  = {de}
}
@article{AlbertBerningBurschkaetal.1981,
  author    = {Albert, Bernhard and Berning, Wilfried and Burschka, Christian and H{\"u}nig, Siegfried and Martin, Hans-Dieter and Prokschy, Frank,},
  title     = {Transanulare Wechselwirkung des Azo-Chromophors inisodrinanalogen Systemen},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-31328},
  year      = {1981},
  abstract  = {No abstract available},
  subject      = {Chemie},
  language  = {de}
}
@phdthesis{Albert2010,
  author    = {Albert, Christian},
  title     = {Differentialdiagnostische Kriterien supratentorieller atypischer teratoid/rhabdoider Tumoren und primitiver neuroektodermaler Tumoren in der Magnetresonanztomographie},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-48497},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2010},
  abstract  = {Der Atypische teratoid/rhabdoide Tumor (ATRT) und der primitive neuroektodermale Tumor (PNET) sind hochmaligne Tumorentit{\"a}ten (WHO-Grad IV) des zentralen Nervensystems, die {\"u}berwiegend im Kleinkindalter auftreten. Beide zeigen eine sehr heterogene morphologische Struktur und sind bisher nur mittels Histopathologie und Immunhistochemie voneinander zu differenzieren. Bisherige Untersuchungen ließen noch keine neuroradiologische Unterscheidbarkeit zwischen beiden Tumorentit{\"a}ten erkennen. Die vorliegende Arbeit befasst sich anhand eines diesbez{\"u}glich einmalig großen Patientenkollektives (23 ATRT, 36 PNET) mit den spezifisichen morphologischen Kriterien des supratentoriellen (st) ATRT und PNET in der Magnetresonanztomographie (MRT). Die Patienten rekrutierten sich aus der multizentrischen Hirntumorstudie HIT 2000 (Teil des Kompetenznetzes der Hirntumorstudien der „Gesellschaft f{\"u}r p{\"a}diatrische Onkologie und H{\"a}matologie"). Retrospektiv wurden MRT-Bilder aus einem Zeitraum von 5 Jahren ausgewertet. Untersucht wurden T1- und T2-Wichtung, nativ und unter Kontrastmittelapplikation. Zur Abgrenzung beider Entit{\"a}ten voneinander wurden verschiedene Kriterien herausgearbeitet. Dazu z{\"a}hlten zun{\"a}chst die Darstellung in der nativen T1-Wichtung, die Sch{\"a}rfe der Tumorbegrenzung, das zeitgleiche Vorliegen von Zysten, {\"O}demen und Blutungen sowie die Auspr{\"a}gung des Kontrastmittel-Enhancements. Als zentrales Ergebnis der Arbeit konnte ein markantes strukturelles Muster des Kontrastmittel-Enhancements herausgearbeitet werden, welches sich als charakteristisch f{\"u}r den stATRT erwies, w{\"a}hrend es nur bei einem sehr geringen Prozentsatz der stPNETs anzutreffen war. Hierbei handelt es sich um ein girlandenf{\"o}rmiges Band, welches den Tumor randst{\"a}ndig um eine zentrale Nekrose herum auskleidet. Dieses als „ATRT-typisch" bezeichnete Muster wiesen zehn der stATRTs (43,5\%) und drei der stPNETs (8,3\%) auf. Dar{\"u}ber hinaus konnte man bei f{\"u}nf stATRTs (21,7\%) Areale mit wie in der Girlande anzutreffenden vesikul{\"a}ren Strukturen aber ohne begleitende zentrale Tumornekrose beobachten. Nur ein stPNET (2,8\%) wies ebenfalls vesikul{\"a}re Anteile ohne zentrale Nekrose auf. Es konnten somit charakteristische Muster identifiziert werden, welche auff{\"a}llig h{\"a}ufig in Kontrastmittel-verst{\"a}rkten T1-gewichteten MRT-Bildern des stATRT in Erscheinung treten, w{\"a}hrend sie bei stPNETs nur ausgesprochen selten vorzufinden sind.},
  subject      = {Differentialdiagnose},
  language  = {de}
}